GGrantIndex
← Leaderboards

William P Fay

Harry S. Truman Memorial Va Hospital

$8,557,177
Attributed
$12,095,798
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,095,798 · 5
VA$0 · 2

By mechanism

U01$5,584,144 · 1
R01$4,588,714 · 3
P01$1,922,940 · 1
I01$0 · 2

Top collaborators

Most similar at Harry S. Truman Memorial Va Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventAtherosclerosisPlasminogen Activator Inhibitor 1MediatingBlood VesselsPathway InteractionsArteriesBaseNovel StrategiesUniversitiesResearch PersonnelPharmaceutical PreparationsMissouriProteinsCell PhysiologyThrombosisHuman DiseaseMyocardial InfarctionCell MotilityCardiovascular SystemInnovationBurden Of IllnessClinically RelevantFibrinolysis

Grant awards (34)

Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence$0
I01 · FY2025 · VA · contact PI
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence$0
I01 · FY2024 · VA · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$123,892
U01 · FY2023 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence$0
I01 · FY2023 · VA · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$980,957
U01 · FY2022 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence$0
I01 · FY2022 · VA · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$980,957
U01 · FY2021 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome$360,227
R01 · FY2021 · HL · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$351,108
U01 · FY2021 · HL · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$1,171,566
U01 · FY2020 · HL · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$980,957
U01 · FY2020 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome$360,212
R01 · FY2020 · HL · contact PI
Midwest Biomedical Accelerator Consortium: MBArC$994,707
U01 · FY2019 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome$362,318
R01 · FY2019 · HL · contact PI
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome$371,803
R01 · FY2018 · HL · contact PI
Role of Fibrinolytic System in Vein Graft Remodeling$0
I01 · FY2016 · VA · contact PI
Role of Fibrinolytic System in Vein Graft Remodeling$0
I01 · FY2015 · VA · contact PI
Role of Fibrinolytic System in Vein Graft Remodeling$0
I01 · FY2014 · VA · contact PI
PAI-1 and Vitronectin in Failure of Coronary Revascularization$351,116
R01 · FY2013 · HL · contact PI
Role of Fibrinolytic System in Vein Graft Remodeling$0
I01 · FY2013 · VA · contact PI
PAI-1 and Vitronectin in Failure of Coronary Revascularization$368,107
R01 · FY2012 · HL · contact PI
Roles of Plasminogen Activator Inhibitor-1 and Vitronectin in Failure of Coronary$371,840
R01 · FY2011 · HL · contact PI
Roles of Plasminogen Activator Inhibitor-1 and Vitronectin in Failure of Coronary$384,746
R01 · FY2010 · HL · contact PI
Regulation of Fibrinolysis at Sites of Arterial Injury$402,951
P01 · FY2007 · HL · contact PI
Regulation of Fibrinolysis at Sites of Arterial Injury$397,445
P01 · FY2006 · HL · contact PI
Regulation of Fibrinolysis at Sites of Arterial Injury$390,350
P01 · FY2005 · HL
Regulation of Fibrinolysis at Sites of Arterial Injury$383,285
P01 · FY2004 · HL
REGULATION OF PLATELET-DEPENDENT THROMBOSIS$328,513
R01 · FY2004 · HL
REGULATION OF PLATELET-DEPENDENT THROMBOSIS$328,721
R01 · FY2003 · HL
REGULATION OF PLATELET-DEPENDENT THROMBOSIS$328,920
R01 · FY2002 · HL
REGULATION OF PLATELET-DEPENDENT THROMBOSIS$331,409
R01 · FY2001 · HL
REGULATION OF FIBRINOLYSIS AT SITES OF ARTERIAL INJURY$135,852
P01 · FY2001 · HL
REGULATION OF PLATELET-DEPENDENT THROMBOSIS$340,782
R01 · FY2000 · HL
REGULATION OF FIBRINOLYSIS AT SITES OF ARTERIAL INJURY$213,057
P01 · FY2000 · HL